About Cipla Biotec
Cipla Biotec is a Healthcare company based in India founded in 2008, and was acquired by Cipla in June 2014. Monoclonal antibodies (mAb) to treat cancers Wet Age-Related Macular Degeneration and Peptide hormone to treat diabetes. The company has 28 employees. Its Indian entity Cipla Pharma And Life Sciences Limited reported revenue of ₹1,598 Cr. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Cipla Biotec (formerly mabpharm) develops monoclonal antibodies and peptide hormones for treatment of cancers, diabetes and Wet Age-Related Macular Degeneration. Its lead product CBT 124, a monoclonal antibody angiogenesis inhibitor which targets multiple cancers is currently under pre-clinical study. Its other products include CBT 125, a peptide hormone which got approval in India to treat diabetes; CBT 127 (mAb) for breast cancer in the development phase and CBT 128 (mAb) for Wet Age-Related Macular Degeneration in the pre-clinical study. On July 17, 2014 Ciplas unit Meditab Specialities acquired Mabpharm and since then serving as a wholly subsidiary unit of Cipla.
- Headquarters Salcete, India
- Employees 28
- Stage Acquired
- SectorsHealthcare
- Website ciplabiotec.com
- Social X
- Acquired by Cipla (Jun 2014)
- Legal Name Cipla Pharma And Life Sciences Limited
- Date of Incorporation 20 Aug, 2008
- Jurisdiction Mumbai, Maharashtra, India
Associated legal entities of Cipla Biotec
Cipla Biotec operates through Cipla Pharma And Life Sciences Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cipla Pharma And Life Sciences Limited CIN U24239MH2008PLC381559 | Active | 20 Aug 2008 | Mumbai, Maharashtra | ₹1,598 Cr | 28 | 8 | View details |
Investors in Cipla Biotec
Cipla Biotec has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cipla.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
APIs, generic drugs, and formulation services are manufactured. | 1935 | cipla.com | Mumbai, India |
Investor details for Cipla Biotec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Cipla Pharma And Life Sciences Limited (Cipla Biotec)
Cipla Pharma And Life Sciences Limited is the primary company behind Cipla Biotec. The board of Cipla Pharma And Life Sciences Limited currently have 5 directors; the longest-serving is Rajendra Kumar Chopra, appointed in 2019. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajendra Kumar Chopra DIN 06942295 | Director | 02 Jan 2019 | 7 yrs 10 mo | Cipla Pharma And Life Sciences Limited |
| Anisha Naresh Udeshi DIN 08757230 | Director | 08 Jun 2020 | 6 yrs 5 mo | Cipla Pharma And Life Sciences Limited |
| Jinesh Chauhan DIN 10085983 | Whole-time director | 01 Apr 2023 | 3 yrs 7 mo | Cipla Pharma And Life Sciences Limited |
| Sunil Jvalaprsad Gupta DIN 10489041 | Managing Director | 02 Feb 2024 | 2 yrs 9 mo | Cipla Pharma And Life Sciences Limited |
| Raju Sunil Mistry DIN 07768108 | Additional Director | 01 Jun 2025 | 1 yr 5 mo | Cipla Pharma And Life Sciences Limited |
Financials of Cipla Biotec
Figures of Cipla Pharma And Life Sciences Limited, the primary company behind Cipla Biotec, for FY 2025. Revenue was ₹1,598 Cr (-2% year on year). Net profit was ₹332 Cr (21% margin). EBITDA was ₹471 Cr (29% margin). Revenue has grown at a compounded annual rate of +336% over three years.
- ₹1,598 CrRevenue · FY 2025 · -2% YoY
- ₹332 CrNet profit · 21% margin
- ₹471 CrEBITDA · 29% margin
- ₹259 CrPaid-up capital
- 28Employees (provident fund records)
- +336%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Cipla Pharma And Life Sciences Limited are on its company page.
Detailed financial statements for Cipla Biotec
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cipla Biotec
2 dated milestones of Cipla Biotec across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Cipla Biotec is founded.
- Exit Acquired by Cipla.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cipla Biotec
Complete news archive for Cipla Biotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cipla Biotec
Cipla Biotec was founded in 2008.
Cipla Biotec is headquartered in India. It is registered at Goa, India.
Cipla Biotec has 28 employees.
The primary company behind Cipla Biotec, Cipla Pharma And Life Sciences Limited, reported revenue of ₹1,598 Cr for FY 2025, down 2% year on year.
Cipla Biotec (formerly mabpharm) develops monoclonal antibodies and peptide hormones for treatment of cancers, diabetes and Wet Age-Related Macular Degeneration. Its lead product CBT 124, a monoclonal antibody angiogenesis inhibitor which targets multiple cancers is currently under pre-clinical study. Its other products include CBT 125, a peptide hormone which got approval in India to treat diabetes; CBT 127 (mAb) for breast cancer in the development phase and CBT 128 (mAb) for Wet Age-Related Macular Degeneration in the pre-clinical study. On July 17, 2014 Ciplas unit Meditab Specialities acquired Mabpharm and since then serving as a wholly subsidiary unit of Cipla.
Cipla Biotec has 1 investor. Key investors include Cipla.
Cipla Biotec operates through Cipla Pharma And Life Sciences Limited.
Yes. Cipla Biotec was acquired by Cipla in June 2014.
The legal entities of Cipla Biotec currently have 8 directors, including Anisha Naresh Udeshi, Sunil Jvalaprsad Gupta, Akshaya Rajendra Kolvankar and others.